(INMD) InMode - Ratings and Ratios
RF, Minimally Invasive, Lasers, Hands-Free
INMD EPS (Earnings per Share)
INMD Revenue
Description: INMD InMode
InMode Ltd (NASDAQ:INMD) is an Israeli‑based public company operating in the Health Care Equipment sub‑industry, focused on minimally invasive aesthetic and medical devices that use proprietary radio‑frequency (RF) technology.
The firm’s market valuation sits just under $1 billion, with a trailing P/E of roughly 6× and a forward P/E near 9×, indicating a low price relative to earnings and modest expectations for near‑term earnings growth. Return on equity exceeds 26%, reflecting efficient capital deployment and high profitability on a lean balance sheet.
Key performance indicators include double‑digit revenue growth over the past three fiscal years, driven by expanding U.S. clinic adoption, international market penetration, and a consumables business that generates recurring cash flow. Gross margins consistently hover around 80%, while operating cash flow conversion remains strong, supporting ongoing R&D investment and strategic acquisitions without reliance on external financing.
Primary economic drivers are the rising demand for elective cosmetic procedures, demographic shifts favoring younger consumers with disposable income, and the company’s ability to secure FDA clearances for new device platforms. Competitive pressures stem from other aesthetic device manufacturers and the broader consumer‑discretionary cycle, making macro‑economic confidence and regulatory timelines critical to sustaining growth.
INMD Stock Overview
| Market Cap in USD | 949m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2019-08-08 |
INMD Stock Ratings
| Growth Rating | -68.3% |
| Fundamental | 72.4% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -27.5% |
| Analyst Rating | 3.43 of 5 |
INMD Dividends
Currently no dividends paidINMD Growth Ratios
| Growth Correlation 3m | 35% |
| Growth Correlation 12m | -68.1% |
| Growth Correlation 5y | -71.3% |
| CAGR 5y | -21.52% |
| CAGR/Max DD 3y | -0.30 |
| CAGR/Mean DD 3y | -0.38 |
| Sharpe Ratio 12m | 0.76 |
| Alpha | 0.16 |
| Beta | 0.488 |
| Volatility | 44.57% |
| Current Volume | 640.8k |
| Average Volume 20d | 798.9k |
| Stop Loss | 14.3 (-4.2%) |
| Signal | 0.00 |
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (178.7m TTM) > 0 and > 6% of Revenue (6% = 24.1m TTM) |
| FCFTA 0.15 (>2.0%) and ΔFCFTA -4.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 142.5% (prev 178.9%; Δ -36.38pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.15 (>3.0%) and CFO 104.8m <= Net Income 178.7m (YES >=105%, WARN >=100%) |
| Net Debt (-210.1m) to EBITDA (123.4m) ratio: -1.70 <= 3.0 (WARN <= 3.5) |
| Current Ratio 9.60 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (63.6m) change vs 12m ago -25.91% (target <= -2.0% for YES) |
| Gross Margin 79.98% (prev 82.27%; Δ -2.29pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 51.21% (prev 48.45%; Δ 2.76pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' 21.87
| (A) 0.81 = (Total Current Assets 638.8m - Total Current Liabilities 66.5m) / Total Assets 708.3m |
| (B) 1.23 = Retained Earnings (Balance) 874.7m / Total Assets 708.3m |
| warn (B) unusual magnitude: 1.23 — check mapping/units |
| (C) 0.16 = EBIT TTM 122.7m / Avg Total Assets 784.1m |
| (D) 10.94 = Book Value of Equity 874.6m / Total Liabilities 79.9m |
| Total Rating: 21.87 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 72.35
| 1. Piotroski 4.0pt = -1.0 |
| 2. FCF Yield 20.09% = 5.0 |
| 3. FCF Margin 25.94% = 6.49 |
| 4. Debt/Equity 0.13 = 2.49 |
| 5. Debt/Ebitda 0.65 = 2.18 |
| 6. ROIC - WACC (= 176.4)% = 12.50 |
| 7. RoE 26.59% = 2.22 |
| 8. Rev. Trend -60.30% = -4.52 |
| 9. EPS Trend -60.02% = -3.00 |
What is the price of INMD shares?
Over the past week, the price has changed by -0.60%, over one month by +4.37%, over three months by +11.67% and over the past year by -14.05%.
Is InMode a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of INMD is around 11.57 USD . This means that INMD is currently overvalued and has a potential downside of -22.51%.
Is INMD a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the INMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 16.3 | 8.8% |
| Analysts Target Price | 16.3 | 8.8% |
| ValueRay Target Price | 12.8 | -14.1% |
Last update: 2025-09-12 04:38
INMD Fundamental Data Overview
CCE Cash And Equivalents = 510.7m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 6.3109
P/E Forward = 8.4531
P/S = 2.3643
P/B = 1.5107
P/EG = 2.9004
Beta = 2.007
Revenue TTM = 401.6m USD
EBIT TTM = 122.7m USD
EBITDA TTM = 123.4m USD
Long Term Debt = 13.4m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 66.5m USD (from totalCurrentLiabilities, last quarter)
Debt = 79.9m USD (Calculated: Short Term 66.5m + Long Term 13.4m)
Net Debt = -210.1m USD (from netDebt column, last quarter)
Enterprise Value = 518.6m USD (949.4m + Debt 79.9m - CCE 510.7m)
Interest Coverage Ratio = unknown (Ebit TTM 122.7m / Interest Expense TTM 0.0)
FCF Yield = 20.09% (FCF TTM 104.2m / Enterprise Value 518.6m)
FCF Margin = 25.94% (FCF TTM 104.2m / Revenue TTM 401.6m)
Net Margin = 44.50% (Net Income TTM 178.7m / Revenue TTM 401.6m)
Gross Margin = 79.98% ((Revenue TTM 401.6m - Cost of Revenue TTM 80.4m) / Revenue TTM)
Tobins Q-Ratio = 0.59 (Enterprise Value 518.6m / Book Value Of Equity 874.6m)
Interest Expense / Debt = 4.12% (Interest Expense 3.29m / Debt 79.9m)
Taxrate = -26.35% (set to none) (-37.8m / 143.5m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 9.60 (Total Current Assets 638.8m / Total Current Liabilities 66.5m)
Debt / Equity = 0.13 (Debt 79.9m / last Quarter total Stockholder Equity 628.4m)
Debt / EBITDA = 0.65 (Net Debt -210.1m / EBITDA 123.4m)
Debt / FCF = 0.77 (Debt 79.9m / FCF TTM 104.2m)
Total Stockholder Equity = 672.1m (last 4 quarters mean)
RoA = 25.23% (Net Income 178.7m, Total Assets 708.3m )
RoE = 26.59% (Net Income TTM 178.7m / Total Stockholder Equity 672.1m)
RoCE = 17.90% (Ebit 122.7m / (Equity 672.1m + L.T.Debt 13.4m))
RoIC = 176.4% (Ebit 122.7m / (Assets 708.3m - Current Assets 638.8m))
WACC = unknown (E(949.4m)/V(1.03b) * Re(7.81%)) + (D(79.9m)/V(1.03b) * Rd(4.12%) * (1-Tc(none)))
Shares Correlation 3-Years: -45.45 | Cagr: -2.58%
Discount Rate = 7.81% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 77.90% ; FCFE base≈129.6m ; Y1≈126.3m ; Y5≈127.1m
Fair Price DCF = 35.74 (DCF Value 2.26b / Shares Outstanding 63.2m; 5y FCF grow -3.68% → 3.0% )
EPS Correlation: -60.02 | EPS CAGR: -11.61% | SUE: 0.91 | # QB: 1
Revenue Correlation: -60.30 | Revenue CAGR: -8.27% | SUE: 0.21 | # QB: 0
Additional Sources for INMD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle